Product Browser

Last updated: 2016/11/27

Product Compare

Product Compare Cancel Click this icon to add products to compare list. Select up to 10 products.

Quick Order (Tutorial)

Input Catalog #,
place order here!
Catalog # :
  • Where to buy
  • Choose your location

KLRC4 Pre-design Chimera RNAi

  • Catalog # : H00008302-R02
  • Visit Frequency :
  • Countries :
  • Specification
  • Product Description:
  • Homo sapiens killer cell lectin-like receptor subfamily C, member 4 (KLRC4), mRNA.
  • Reactivity:
  • Human
  • Supplied Product:
  • DEPC water
  • Target Refseq:
  • NM_013431
  • Storage Instruction:
  • Store at -20°C, do not exceed 4 - 5 freeze-thaw cycles to ensure product integrity.
  • Note:
  • Position of the Chimera RNAi.

  • Publication Reference
  • Applications
  • RNAi Knockdown
  • Application Image
  • RNAi Knockdown
  • Gene Information
  • Entrez GeneID:
  • 8302
  • Gene Name:
  • KLRC4
  • Gene Alias:
  • FLJ17759,FLJ78582,NKG2-F,NKG2F
  • Gene Description:
  • killer cell lectin-like receptor subfamily C, member 4
  • Gene Summary:
  • Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. KLRC4 is a member of the NKG2 group which are expressed primarily in natural killer (NK) cells and encodes a family of transmembrane proteins characterized by a type II membrane orientation (extracellular C terminus) and the presence of a C-type lectin domain. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed on NK cells. The 3' end of the KLRC4 transcript includes the first non-coding exon found at the 5' end of the adjacent D12S2489E gene transcript. [provided by RefSeq
  • Other Designations:
  • -
  • RSS
  • YouTube
  • Linkedin
  • Facebook